VIVLODEX Drug Patent Profile

Which patents cover Vivlodex, and what generic alternatives are available?

Vivlodex is a drug marketed by Iceutica Operations and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixteen patent family members in sixteen countries.

The generic ingredient in VIVLODEX is meloxicam. There are twenty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vivlodex

A generic version of VIVLODEX was approved as meloxicam by AVONDALE PHARMS on June 1^st, 2004.

Summary for VIVLODEX

International Patents:	16
US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	112
Patent Applications:	2,542
Drug Prices:	Drug price information for VIVLODEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIVLODEX
What excipients (inactive ingredients) are in VIVLODEX?	VIVLODEX excipients list
DailyMed Link:	VIVLODEX at DailyMed

See drug prices for VIVLODEX

See drug sales revenues for VIVLODEX

Paragraph IV (Patent) Challenges for VIVLODEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIVLODEX	Capsules	meloxicam	5 mg and 10 mg	207233	1	2017-01-09

US Patents and Regulatory Information for VIVLODEX

VIVLODEX is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-001	Oct 22, 2015		DISCN	Yes	No
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-002	Oct 22, 2015		DISCN	Yes	No			Y
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-001	Oct 22, 2015		DISCN	Yes	No			Y

EU/EMA Drug Approvals for VIVLODEX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Norbrook Laboratories (Ireland) Limited	Loxicom	meloxicam	EMEA/V/C/000141DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2009-02-10
Le Vet Beheer B.V.	Novaquin	meloxicam	EMEA/V/C/003866Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.	Authorised	no	no	no	2015-09-08
Le Vet Beheer B.V	Meloxidolor	meloxicam	EMEA/V/C/002590DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2013-04-22

International Patents for VIVLODEX

See the table below for patents covering VIVLODEX around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015274838	A novel formulation of meloxicam
Brazil	112016027435	formulação inovadora de meloxicam
Canada	2951383	NOUVELLE FORMULATION DE MELOXICAM (A NOVEL FORMULATION OF MELOXICAM)

Last updated: June 7, 2026

Vivlodex (meloxicam) Market Dynamics and Financial Trajectory: Pricing, Competition, Exclusivity Risk, and Revenue Outlook

Executive summary: Vivlodex (meloxicam) is a branded NSAID competing in a crowded generic-dominated market. Financial trajectory is driven less by patent leverage and more by (1) how quickly generics compress net price, (2) residual payer access for brand tablets, (3) channel inventory and contract renewals, and (4) any remaining IP/exclusivity or lifecycle protections that slow full price erosion. For most forecasts, the dominant variable is the timing and depth of generic penetration for meloxicam products in the same strength/dosage form mix, not long-duration brand exclusivity.

---

What is Vivlodex (meloxicam) and how does it fit into the NSAID market?

Vivlodex is an oral NSAID containing meloxicam, positioned for pain management. In the US, meloxicam is a mature molecule and trades in a market where branded presence is limited by extensive generic availability across common oral NSAID indications (osteoarthritis, rheumatoid arthritis historically, and related pain pathways).

Market structure for meloxicam:

• Generic availability is extensive across strengths and dosing schedules, leading to sustained net-price pressure on brands.
• Formulary access is payer-contract driven, with NSAID coverage often near-parity among low-cost generics.
• Clinical positioning for meloxicam typically does not create durable differentiation once therapeutic equivalents are widely adopted.

Implication for financial trajectory: branded revenue tends to be highly sensitive to formulary status, pharmacy benefit manager (PBM) tier placement, and net price versus generic baselines, rather than sustained “new product” demand.

---

What patents protect Vivlodex, and how does patent expiration shape revenue erosion?

Vivlodex’s financial path depends on whether any remaining composition, method, polymorph, or formulation protections delayed generic substitution for its specific capsule/tablet strengths or dosing regimens.

Revenue impact mechanics:

1. Orange Book coverage and “next generic entry” timing determine when competing labels can launch without infringing.
2. If exclusivity or listed patents remain in force, generic launch timing can slip and preserve brand net sales longer.
3. If patents are fully expired or not meaningfully asserted, branded revenue typically declines toward the generic-class pricing equilibrium.

Practical takeaway: for mature meloxicam brands, the most common pattern is post-launch price compression once core listed protections lapse, followed by revenue drift tied to contract churn and brand loyalty rather than competitive moat.

(No patent dataset was supplied in the prompt. A complete, accurate Vivlodex patent-portfolio map requires Orange Book listing and jurisdiction-specific filings; those are not included here.)

---

When does Vivlodex lose exclusivity, and what does that mean for net price?

For branded NSAIDs with generic molecule competition, “losing exclusivity” usually translates into:

• Launch of authorized generics and/or full generics for the same strength and dosage form, followed by
• Net price resets driven by PBMs and wholesaler contracting, and
• Higher substitution rates at the point of sale.

Financial translation:

• Brand gross-to-net often deteriorates after generic launches because rebates and performance payments rise to defend shelf and dispense share.
• Even if prescription volume holds initially, net sales typically fall faster than units once price compression accelerates.

(A precise exclusivity timeline cannot be produced from the provided input.)

---

How many competitors does Vivlodex face, and how fast does generic substitution happen?

Vivlodex competes in the meloxicam class against:

• Multiple generic meloxicam products (same molecule, different manufacturers)
• Other branded NSAIDs (different actives) depending on patient and prescriber switching behavior
• Therapy-class alternatives (COX-2 inhibitors, topical NSAIDs, other oral NSAIDs)

Competition dynamics that drive the financial trajectory:

• Dispense share follows PBM tiering, not prescribing intent.
• Once generics become default, brand volume becomes “defended” only by payer-specific contracting.
• Switching friction is low in an oral generic NSAID class.

Implication: branded sales can remain non-zero for years, but the slope is usually negative after key generic milestones.

---

What does the Orange Book status of Vivlodex indicate about generic entry risk?

The Orange Book status (patent listings and exclusivity codes) typically determines:

• Whether a generic filing can be made under Paragraph IV (challenge) or 505(b)(2) pathways, and
• Whether a generic launch is permitted “at risk” or must wait for patent expiry.

Generic entry risk framework:

• Low risk when listed patents remain enforceable near-term and blocking patents are expected to be sustained.
• High risk when no blocking patents remain or when the patent estate is likely to be narrowed/invalidated.

(Orange Book data is not included in the prompt, so a determination of Vivlodex listing strength cannot be made accurately here.)

---

How strong is the patent estate for Vivlodex versus other meloxicam products?

For mature drugs like meloxicam, patent strength typically matters less than:

• Whether Vivlodex has unique formulation/form factor protections that slow substitution for the exact dosage form; and
• Whether the market has multiple therapeutic equivalent options that let payers steer away without clinical penalty.

What to measure for “estate strength” (if Orange Book and litigation records are available):

• Count of unexpired listed patents by category (composition, method, formulation, use)
• Proximity to expiry dates (weighted by remaining life)
• Whether patents have been asserted in litigation
• Whether any settlements removed the largest blocking patents early

(Patent estate quantification requires primary Orange Book and litigation inputs not provided.)

---

What formulation patents and lifecycle protections apply to Vivlodex?

Brand NSAID lifecycle protections commonly target:

• Solid-state form (polymorph/hydrate),
• Particle size distribution or morphology,
• Manufacturing process for a specific solid form,
• Dosage form design affecting pharmacokinetics.

Why this matters financially: if lifecycle protections are specific to Vivlodex’s formulation, generics may require:

• Additional ANDA process controls,
• Bioequivalence work specific to the protected form, or
• Time spent waiting on specific patent expiry rather than broad molecule-level expiry.

For meloxicam-class drugs, however, generic substitution is frequently possible with multiple unprotected generic forms, which limits the ability of lifecycle patents to sustain premium pricing.

(Formulation patent list not supplied; no accurate claims can be made.)

---

What Vivlodex patent litigation affects generic launch timing?

Patent litigation typically affects financial trajectory by:

• Triggering automatic stays (if applicable),
• Forcing “at risk” launches or design-arounds,
• Resulting in settlement-driven launch calendars.

Market-financial effect sequence:

1. Patent suit filed
2. Court or parties produce interim rulings
3. Settlement sets generic entry date(s)
4. Net sales decline after first product launches
5. Subsequent generic waves deepen price compression

(No litigation record was supplied.)

---

What financial trajectory has Vivlodex shown, including revenue and prescription volume trends?

A full financial trajectory requires:

• Brand net sales by year (FDA OGD or company financial statements),
• Prescription volume data (IQVIA/DRG/Payer data),
• Share by strength and formulation,
• Net price and rebate rates.

None of that numeric financial material is present in the prompt, so a complete trajectory with quantified years cannot be generated.

What can be stated from market mechanics:

• As with other genericized NSAIDs, Vivlodex’s long-run branded revenue tends toward a low single-digit share of total class dollars after sustained generic penetration, unless it has a unique defended payer niche.
• Brand growth is generally capped by generic substitution; any incremental lift usually reflects formulary wins, switching inertia, or channel inventory timing rather than structural demand expansion.

(Quantified revenue figures cannot be produced from the provided input.)

---

How do net pricing, rebates, and wholesaler contracting drive Vivlodex profitability?

Even without revenue numbers, profitability is typically shaped by:

• Gross-to-net compression after generic entries (rebates escalate to defend access)
• Contracting concentration risk (losing a major PBM contract is a step-function revenue event)
• Inventory and chargebacks during transition to generic availability
• Promotion spend tied to maintaining dispense share

Financial implication: once generics dominate, the brand can remain on formularies but must often pay for visibility via rebates, raising breakeven thresholds.

---

How does Vivlodex compare with other branded NSAIDs and meloxicam brands on commercial momentum?

Vivlodex’s competitive position depends on:

• Whether competing brands have stronger differentiation (for example, topical delivery systems, different actives with distinct payer preferences, or better managed-care contracting),
• Whether those brands benefit from stronger or still-live lifecycle IP,
• Whether any brands have higher patient adherence due to dosing simplicity or tolerability perceptions.

In a generic molecule class, most brands converge to:

• Similar clinical outcomes
• Different contracting outcomes
• Different net price realized by PBM tier position

Implication: Vivlodex’s trajectory is more likely to be “contract and access-driven” than “innovation-driven” versus other NSAIDs once meloxicam generics proliferate.

---

What generic entry risks exist for Vivlodex and what are the likely launch scenarios?

Generic entry scenarios that impact branded financial outcomes usually fall into three buckets:

1. Full ANDA launch upon patent expiry for the exact dosage form/strength
2. Authorized generic launch by an original brand steward, typically with a faster price reset
3. Multiple waves from different manufacturers leading to sequential net price drops and dispense-share erosion

Brand-protection levers during late lifecycle:

• Contractual rebates and formulary placement
• Product switching resistance with specific strength/form factor
• Targeting lines of therapy where prescribers have preference for meloxicam

(No ANDA or litigation docket was supplied.)

---

What is the FDA regulatory status of Vivlodex, and how does it affect competitive timing?

FDA-related competitive timing is driven by:

• ANDA approval timing (for generics)
• Bioequivalence requirements and labeling scope
• Any required label modifications following litigation or post-marketing safety updates

Financial effect: regulatory acceptance typically determines:

• When generics can market
• When pharmacists can substitute
• Whether brand can claim exclusivity for a labeling or dosage scope

(FDA regulatory timeline details require primary FDA/Orange Book inputs not provided.)

---

Which companies are likely to be challenging Vivlodex, and what does that mean for revenue exposure?

Molecule-level NSAID challenges typically come from:

• Generic manufacturers across multiple ANDA applicants
• Authorized generic stewards (if any)
• Sometimes “carve-out” applicants targeting specific strengths

Revenue exposure model for branded NSAIDs:

• Revenue risk spikes at the first meaningful generic launch that triggers payer line-item substitution
• Risk extends again when additional strengths or dosage forms gain broad uptake
• Risk is highest where Vivlodex had its largest share of total prescriptions

(No applicant list was supplied.)

---

How does manufacturing and IP complexity raise barriers for generic entrants to Vivlodex?

For solid oral products, the typical barrier is not clinical development but:

• Manufacturing equivalence and consistent solid-state performance
• Ensuring bioequivalence
• Avoiding formulation or manufacturing process claims if still protected

Financial relevance: if generics face complexity in matching a protected formulation, they may delay launch, sustaining higher brand prices longer.

(No formulation/process patent details were supplied.)

---

Key Takeaways

• Vivlodex operates in a mature meloxicam market where generic substitution is the main driver of branded net sales erosion.
• The financial trajectory is typically governed by timing of generic entry linked to Orange Book listings, exclusivity, and any litigation-driven stays or settlements.
• Profitability is heavily shaped by gross-to-net compression after generics and by PBM contract defense.
• Without Orange Book, litigation, and annual sales/volume figures, a quantified revenue forecast or year-by-year trajectory cannot be produced from the provided input.

---

FAQs

1. What factors most quickly reduce Vivlodex net sales after generic meloxicam launches?
2. How does PBM formulary tier placement change Vivlodex prescription share over time?
3. What is the typical sequence of generics entering an oral NSAID class after key patent expiry?
4. Do formulation or solid-state protections meaningfully delay substitution for branded meloxicam products?
5. How do rebate and chargeback dynamics change when a brand NSAID loses its strongest payer contracts?

---

References

No sources were provided in the prompt.